바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.57 No.1
Citation Share

Diagnostic Utility of Pleural Fluid CEA and CYFRA 21-1 for Malignant Pleural Effusions

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2004, v.57 no.1, pp.32-36










& (2004). Diagnostic Utility of Pleural Fluid CEA and CYFRA 21-1 for Malignant Pleural Effusions. Tuberculosis & Respiratory Diseases, 57(1), 32-36.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background:The purpose of this study was to evaluate the usefulness of the pleural fluid carcinoembryonic antigen (CEA) and cytokeratin fragment 19 (CYFRA 21-1) tumor markers as complementary tools for the diagnosis of malignant pleural effusions.Patients and Methods:The levels of pleural and serum CEA and CYFRA 21-1 were prospectively assayed in 222 patients with pleural effusions (150 benign effusions, 57 bronchogenic carcinomas and 15 metastatic carcinomas).Results:The levels of pleural fluid CEA and CYFRA 21-1 in the malignant effusions were significantly higher than those in the benign effusions. With a specificity of 95%, the cut off values for the CEA and CYFRA 21-1 in pleural effusions were 5 and 89 ng/ml, respectively. The diagnostic sensitivities of the pleural fluid CEA and CYFRA 21-1 in malignant effusions were 72 and 54%, respectively, whereas using a combination of the two, the sensitivity increased to 87% (p<0.05).Conclusions : These findings suggest that a combination of the pleural fluid CEA and CYFRA 21-1 in pleural effusions can be useful in the diagnosis of malignant pleural effusions.(Tuberc Respir Dis 2004; 57:32-36)

keywords
CEA, CYFRA 21-1, Malignant pleural effusions.

Reference

1.

(1985) Comparison of needle biopsy with cytologic analysis for the evaluation of pleural effusion:analysis of 414 cases,

2.

(1997) Elevated level of carcinoembryonic antigen in nonmalignant pleural effusions,

3.

(1993) CYFRA 21-1.A new marker in lung cancer,

4.

a sensitive and specific new tumour marker for squamous cell lung cancer Report of the first European multicentre evaluation,

5.

(chest1980) agnostic value of carcinoembryonic antigen in exuꠀ,

6.

(1988) Tumor markers in pleural effusion diagnosis,

7.

(1996) Assessment of serum CYFRA 21-1 in lung cancer,

8.

(1993) Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer,

9.

(1996) Evaluation of CYFRA 21-1 in malignant and benign pleural effusions,

10.

(1995) Clinical evaluation of CYFRA 21-1 in malignant pleural fluids,

11.

(1999) Diagnostic utility of CYFRA 21-1, carcinoembryonic antigen, CA 125, neuron specific enolase, and squamous cell antigen level deterꠀminations in the serum and pleural fluid of patients with pleural effusions,

12.

(1999) Diagnostic value of CYFRA 21-1 in diffeꠀrential diagnosis of pleural effusion,

13.

(1993) Clinical significance of the combined assay of pleural fluid ADA activity and CEA level in the various pleural effusions,

14.

(1998) Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions,

15.

(2001) Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma,

16.

(1996) CEA,CA 15-3 and CYFRA 21-1 in serum and pleural fluid of patients with pleural effusions,

17.

(2001) Diagnostic value of CEA, CA 15-3, CA 19-9, CYFRA 21-1, NSE and TSA assay in pleural effusions,

Tuberculosis & Respiratory Diseases

e-Submission OA Policy